Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Checkpoint Therapeutics Inc (CKPT)
NASDAQ:CKPT
RESEARCH TOOLSreports
Holding CKPT?
Track your performance easily
CKPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.30 - $3.62
Previous Close$2.46
Volume331.73K
Average Volume (3M)393.43K
Market Cap
$110.74M
Enterprise Value$105.79M
Total Cash (Recent Filing)$4.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 06, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding45,017,841
10 Day Avg. Volume379,263
30 Day Avg. Volume393,433
Standard Deviation0.20
R-Squared0.12
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-7.03
Price to Sales (P/S)1454.42
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.03K
Enterprise Value/Gross Profit1.03K
Enterprise Value/Ebitda-2.65
Forecast
1Y Price Target
$12.00Price Target Upside393.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Checkpoint Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's earnings per share for the fourth quarter and full year were better than expected, beating both the analyst's and consensus estimates.
Market PotentialCosibelimab is a differentiated CKI therapy with significant market potential.
Regulatory PathwayThe CRL did not raise concerns about the clinical data, safety, or labeling of cosibelimab, suggesting that the issues are not related to the drug's efficacy or safety.
Bears Say
FDA DecisionThe FDA issued a Complete Response Letter (CRL) for cosibelimab, which is a delay in the regulatory approval process.
Manufacturing IssuesThe reason for the CRL is due to findings reported from a multi-sponsor inspection of the company's third-party contract manufacturing organization, Samsung Biologics.
Regulatory ApprovalThe CRL remains a setback for the regulatory approval timeline of cosibelimab.
---
Ownership Overview
12.23% Insiders
3.46% Mutual Funds
10.43% Other Institutional Investors
73.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CKPT FAQ
What was Checkpoint Therapeutics Inc’s price range in the past 12 months?
Checkpoint Therapeutics Inc lowest stock price was $1.30 and its highest was $3.62 in the past 12 months.
What is Checkpoint Therapeutics Inc’s market cap?
Currently, no data Available
When is Checkpoint Therapeutics Inc’s upcoming earnings report date?
Checkpoint Therapeutics Inc’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Checkpoint Therapeutics Inc’s earnings last quarter?
Checkpoint Therapeutics Inc released its earnings results on Aug 12, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.305 by $0.125.
Is Checkpoint Therapeutics Inc overvalued?
According to Wall Street analysts Checkpoint Therapeutics Inc’s price is currently Undervalued.
Does Checkpoint Therapeutics Inc pay dividends?
Checkpoint Therapeutics Inc does not currently pay dividends.
What is Checkpoint Therapeutics Inc’s EPS estimate?
Checkpoint Therapeutics Inc’s EPS estimate is -$0.15.
How many shares outstanding does Checkpoint Therapeutics Inc have?
Checkpoint Therapeutics Inc has 44,317,840 shares outstanding.
What happened to Checkpoint Therapeutics Inc’s price movement after its last earnings report?
Checkpoint Therapeutics Inc reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.305. Following the earnings report the stock price went up 2.667%.
Which hedge fund is a major shareholder of Checkpoint Therapeutics Inc?
Currently, no hedge funds are holding shares in CKPT
---
Checkpoint Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (393.83% Upside)
$12.00 (393.83% Upside)
Blogger Sentiment
Bullish
CKPT Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $77.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.00%
Trailing 12-Months
Company Description
Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
---
CKPT Stock 12 Month Forecast
Average Price Target
$12.00
▲(393.83% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Oncternal Therapeutics
―
Fennec Pharmaceuticals
―
Molecular Templates
―
Best Analysts Covering CKPT
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+0.69%
reiterated a buy rating last month
Copying Thomas Flaten's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +0.69% per trade.
---